Proposed Collection; Comment Request; Assessment of the Use of Special Funding on Research on Type 1 Diabetes Provided by the Balanced Budget Act of 1997, the FY 2001 Consolidated Appropriations Act, and the Public Health Service Act Amendment for Diabetes, 11994-11995 [05-4674]
Download as PDF
11994
Federal Register / Vol. 70, No. 46 / Thursday, March 10, 2005 / Notices
Effective
date
Subject name, address
CHICAGO, IL
PISANO, SALLIE ......................
LACEY, WA
POOLE, WILLIAM ....................
EAGLESVILLE, TN
POULSEN, JERRY W ..............
VALLEY CITY, UT
POYATOS, DANILO .................
VICTORVILLE, CA
PRONTO, DAVID .....................
HUDSON FALLS, NY
PRUGH, JAMES .......................
SCOTTSDALE, AZ
RAIMAN, GARII ........................
CONCORD, CA
ROSS, LINDA ...........................
EL DORADO, KS
SABATINO, DAVID ..................
ELIZABETHTON, TN
SARVIS, AMANDA ...................
FREMONT, NC
SAVAGE, SANDRA ..................
S BOSTON, MA
SAYED, SAQUIB ......................
CRANFORD, NJ
SCHAEFFER, BRANDON ........
CHICAGO, IL
SCHWARZ, ANN ......................
RANDOLPH, MA
SCOTT, OTIS ...........................
ABINGTON, PA
SEJALBO, MARYANN .............
HAYWARD, CA
SHELL, JOAN-MARIE ..............
PORT HADLOCK, WA
SHERMAN, AHRON .................
EUREKA, CA
SHINDORE, SHREELAL ..........
NAPLES, FL
SHORT, LEA ANN ...................
NEW ALBANY, IN
SILVA, LINDA ...........................
IONE, CA
SIMPSON, LISA .......................
LOUISVILLE, KY
SMITH, LESLIE ........................
TEMPE, AZ
SMITH, SUSAN ........................
ROCKFORD, IL
SMITH, TRICIA .........................
OSSIPEE, NH
SOUSA, BONNIE .....................
STOCKTON, CA
STAPLETON, KELLY ...............
CRESTWOOD, IL
STELLHORN, JEANNE ............
CAHOKIA, IL
STEVENS, ANNA .....................
ROOSEVELT, UT
STOLLOF, KELLY ....................
INDIO, CA
STROMBERG, WILLIAM ..........
DE SOTO, IL
SUPPLEE, PENNY ...................
WEST CHESTER, PA
SUSS, BEVERLY .....................
GRAFTON, MA
SUTTON, CURTIS ...................
LAYTON, UT
TAYLOR, REGINA ...................
CHICAGO, IL
TEE, MIKE ................................
AURORA, CO
VAHLE, TREVOR .....................
VerDate jul<14>2003
18:28 Mar 09, 2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
Subject name, address
FRUITA, CO
VALENCIA, MARIA ..................
DENVER, CO
VALENTINE, CHRISTINE ........
RICHMOND, VA
VANDENBOS, GREGORY .......
RENO, NV
VAWTER, KAREN ....................
COEUR D’ALENE, ID
WALLACE, PATRICK ...............
ABINGDON, VA
WIJNHAMER, JAN ...................
BELLINGHAM, WA
WILLIAMS, MICHELLE ............
PAINTSVILLE, KY
WILSON, DONNA ....................
JASPER, TX
WRIGHT, STEVIE ....................
SEYMOUR, TN
YOUNG, SANDRA ...................
CARTERVILLE, IL
ZEGARRA, GLORIA .................
GLENDALE, CA
3/20/2005
3/20/2005
3/20/2005
MED-CON, INC ........................
PAINTSVILLE, KY
PRICE, HARRY ........................
MARTINSBURG, VA
SHAW, JOHN ...........................
PAINTSVILLE, KY
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
AMERICAN FAMILY PHARMACEUTICALS, INC ..................
NAPLES, FL
CONVENIENT MEDICAL
SERVICES, INC ....................
NAPLES, FL
LADD MANAGEMENT CORPORATION ...........................
LEAWOOD, KS
MARIN CHIROPRACTIC, INC
VAN NUYS, CA
MICHAEL E SMITH, D P M, P
A ............................................
ORLANDO, FL
MOBILE DENTISTRY, LLC ......
NEW CASTLE, PA
PAIN RELIEF MEDICAL CENTER .......................................
VAN NUYS, CA
S FT MYERS MEDICAL CENTER, INC ...............................
FT MYERS, FL
SHREELAL M SHINDORE,
MD, PA ..................................
NAPLES, FL
SYNERGISTICS MEDICAL
CARE PA ..............................
LEAWOOD, KS
3/20/2005
3/20/2005
Jkt 205001
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
BAKER, WALTER ....................
VALLEJO, CA
BARNETT, RUTH .....................
DETROIT, MI
BELL, HERMAN .......................
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Subject name, address
LOS ANGELES, CA
CHIANG, PHILIP ......................
MOUNTAIN VIEW, CA
FERNANDO, ANTONIO ...........
PHILADELPHIA, PA
LINDLY, MAURICE ..................
SALINAS, CA
MULLINAX, JEFFREY ..............
WINDSOR, CA
NEWBY, EDGAR ......................
LAWTON, OK
PASCALE, MICHELE ...............
AUGUSTA, GA
RAPPA, RICHARD ...................
N HAVEN, CT
Effective
date
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
CMP
3/20/2005
3/20/2005
3/20/2005
12/29/2004
O’CONNOR, THOMAS .............
MILWAUKEE, WI
2/28/2005
Dated: March 2, 2005.
Katherine B. Petrowski,
Director, Exclusions Staff, Office of Inspector
General.
[FR Doc. 05–4680 Filed 3–9–05; 8:45 am]
BILLING CODE 4150–04–P
9/20/2004
12/29/2004
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Assessment of the Use of
3/20/2005 Special Funding on Research on Type
1 Diabetes Provided by the Balanced
Budget Act of 1997, the FY 2001
3/20/2005 Consolidated Appropriations Act, and
the Public Health Service Act
3/20/2005 Amendment for Diabetes
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
3/20/2005
DEFAULT ON HEAL LOAN
3/20/2005
3/20/2005
3/20/2005
OWNED/CONTROLLED BY CONVICTED
ENTITIES
3/20/2005
3/20/2005
3/20/2005
FRAUD/KICKBACKS/PROHIBITED ACTS/
SETTLEMENT AGREEMENTS
3/20/2005
3/20/2005
Effective
date
3/20/2005
2/1/2005
3/20/2005
SUMMARY: In compliance with the
requirement of section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK),
the National Institutes of Health (NIH),
will publish periodic summaries of
proposed projects to be submitted to the
Office of Management and Budget
(OMB) for review and approval.
Proposed Collection: Title:
Assessment of the Use of Special
Funding for Research on Type 1
Diabetes Provided by the Balanced
Budget Act of 1997 (Pub. L. 105–33), the
FY 2001 Consolidated Appropriations
Act (Pub. L. 106–554), and the Public
Health Service Act Amendment for
Diabetes (Pub. L. 107–360). Type of
Information Collection Request:
Revision, OMB control number 0925–
0503; expiration date: 06/30/2005. Need
and Use of Information Collection: This
E:\FR\FM\10MRN1.SGM
10MRN1
Federal Register / Vol. 70, No. 46 / Thursday, March 10, 2005 / Notices
survey will be one source of input into
a statutorily mandated assessment and
report to the Congress on special
funding for research on type 1 diabetes
provided by the Balanced Budget Act of
1997, (Pub. L. 105–33), the FY 2001
Consolidated Appropriations Act, (Pub.
L. 106–554), and the Public Health
Service Act Amendment for Diabetes,
(Pub. L. 107–360). Collectively, these
Acts provided $1.14 billion in special
funds to the Department of Health and
Human Services (HHS) for research
aimed at understanding, treating and
preventing type 1 diabetes and its
complications. The Secretary of HHS
subsequently designated to NIDDK the
lead responsibility in the Department
for developing a process for allocation
of these funds. The primary objective of
the survey is to gain information, via a
brief questionnaire, from NIH research
grantees, who were the primary
recipients of these special funds,
concerning their views on the impact of
the type 1 diabetes research funding
with respect to: (1) Advancing scientific
accomplishments involving innovative,
clinically relevant, and
multidisciplinary research on type 1
diabetes; (2) developing resources or
reagents useful for type 1 diabetes
research; and (3) increasing the number
and quality of type 1 diabetes
investigators. The responses will
provide valuable information
concerning how the funds have
facilitated research as intended by these
Acts of Congress. The results will also
help determine how research progress
from these special congressional
initiatives fits within the continuum of
diabetes research, and how these funds
have contributed to the field of type 1
diabetes research and NIH efforts to
combat this challenging health problem.
Information from this study will aid in
evaluation of the process by which the
research goals for use of the special type
1 diabetes funds have been developed
and are being pursued. Responses
already collected from this survey were
analyzed as part of an interim program
assessment that was published by the
NIDDK in April, 2003 https://
www.niddk.nih.gov/federal/planning/
type 1_specialfund/. This revised survey
will contribute to a statutorily mandated
report, due to Congress on January 1,
2007, evaluating the process and efforts
under this program and assessing
research initiatives funded by these Acts
of Congress.
Frequency of Response: The initial
survey will require a one time response;
though, respondents may be contacted
again in the event of future
congressionally mandated reports on the
VerDate jul<14>2003
18:28 Mar 09, 2005
Jkt 205001
use of the special type 1 diabetes
research funds.
Affected Public: Research scientists
who received the special funds about
which Congress has mandated in law
the requirements for an evaluation
report. Type of Respondents: Laboratory
and clinical investigators who have
received support from the special type
1 diabetes funds provided under the
laws previously cited. The annual
reporting burden is as follows:
Estimated Number of Respondents: 500;
Estimated Number of Responses per
Respondent: 1 (Respondents will be
given one questionnaire containing an
estimated fifteen questions.); Average
Burden Hours Per Response: 1; and
Estimated Total Annual Burden Hours
Requested: 500. The annualized total
cost to respondents is estimated at:
$25,000. It is expected that the
respondents will be contacted vie e-mail
and that their responses will be
collected through an Internet-accessible
questionnaire. These measures will
reduce the burden on the respondents
and the overall costs of administering
the study. Because different types of
awards have been made with the special
type 1 diabetes funds, the questionnaire
may be tailored such that respondents
will only be asked to answer a subset of
questions that pertain to their particular
type of award(s). No respondent will be
asked to answer more than a total of
fifteen questions, at least one-third of
which will be answered with a ‘‘yes’’ or
‘‘no’’ or a one-word response. There are
no Capital Costs, Operating or
Maintenance Costs to report.
Request For Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
11995
instruments, contact Dr. Shefa Gordon,
Office of Scientific Program and Policy
Analysis, NIDDK, NIH, Building 31,
Room 9A31, 9000 Rockville Pike,
Bethesda, MD 20892, or call non-tollfree number 301–496–6623 or e-mail
your request, including your address to:
gordonshefa@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: March 2, 2005.
Lynell Nelson,
Project Clearance Liaison, NIDDK, National
Institutes of Health.
[FR Doc. 05–4674 Filed 3–9–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: (301)
496–7057; fax: (301) 402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Dimer Inhibitory Peptides of CXCR4 as
a Possible Novel Therapy for Cancer
Jinhai Wang and Michael Norcross
(FDA),
DHHS Reference No. E–037–2005/0—
Research Tool,
Licensing Contact: John Stansberry;
(301) 435–5236;
stansbej@mail.nih.gov.
This invention may control or inhibit
cancer metastases by targeting
E:\FR\FM\10MRN1.SGM
10MRN1
Agencies
[Federal Register Volume 70, Number 46 (Thursday, March 10, 2005)]
[Notices]
[Pages 11994-11995]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4674]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request; Assessment of the Use of
Special Funding on Research on Type 1 Diabetes Provided by the Balanced
Budget Act of 1997, the FY 2001 Consolidated Appropriations Act, and
the Public Health Service Act Amendment for Diabetes
SUMMARY: In compliance with the requirement of section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK), the National
Institutes of Health (NIH), will publish periodic summaries of proposed
projects to be submitted to the Office of Management and Budget (OMB)
for review and approval.
Proposed Collection: Title: Assessment of the Use of Special
Funding for Research on Type 1 Diabetes Provided by the Balanced Budget
Act of 1997 (Pub. L. 105-33), the FY 2001 Consolidated Appropriations
Act (Pub. L. 106-554), and the Public Health Service Act Amendment for
Diabetes (Pub. L. 107-360). Type of Information Collection Request:
Revision, OMB control number 0925-0503; expiration date: 06/30/2005.
Need and Use of Information Collection: This
[[Page 11995]]
survey will be one source of input into a statutorily mandated
assessment and report to the Congress on special funding for research
on type 1 diabetes provided by the Balanced Budget Act of 1997, (Pub.
L. 105-33), the FY 2001 Consolidated Appropriations Act, (Pub. L. 106-
554), and the Public Health Service Act Amendment for Diabetes, (Pub.
L. 107-360). Collectively, these Acts provided $1.14 billion in special
funds to the Department of Health and Human Services (HHS) for research
aimed at understanding, treating and preventing type 1 diabetes and its
complications. The Secretary of HHS subsequently designated to NIDDK
the lead responsibility in the Department for developing a process for
allocation of these funds. The primary objective of the survey is to
gain information, via a brief questionnaire, from NIH research
grantees, who were the primary recipients of these special funds,
concerning their views on the impact of the type 1 diabetes research
funding with respect to: (1) Advancing scientific accomplishments
involving innovative, clinically relevant, and multidisciplinary
research on type 1 diabetes; (2) developing resources or reagents
useful for type 1 diabetes research; and (3) increasing the number and
quality of type 1 diabetes investigators. The responses will provide
valuable information concerning how the funds have facilitated research
as intended by these Acts of Congress. The results will also help
determine how research progress from these special congressional
initiatives fits within the continuum of diabetes research, and how
these funds have contributed to the field of type 1 diabetes research
and NIH efforts to combat this challenging health problem. Information
from this study will aid in evaluation of the process by which the
research goals for use of the special type 1 diabetes funds have been
developed and are being pursued. Responses already collected from this
survey were analyzed as part of an interim program assessment that was
published by the NIDDK in April, 2003 https://www.niddk.nih.gov/federal/
planning/type 1--specialfund/. This revised survey will contribute to a
statutorily mandated report, due to Congress on January 1, 2007,
evaluating the process and efforts under this program and assessing
research initiatives funded by these Acts of Congress.
Frequency of Response: The initial survey will require a one time
response; though, respondents may be contacted again in the event of
future congressionally mandated reports on the use of the special type
1 diabetes research funds.
Affected Public: Research scientists who received the special funds
about which Congress has mandated in law the requirements for an
evaluation report. Type of Respondents: Laboratory and clinical
investigators who have received support from the special type 1
diabetes funds provided under the laws previously cited. The annual
reporting burden is as follows: Estimated Number of Respondents: 500;
Estimated Number of Responses per Respondent: 1 (Respondents will be
given one questionnaire containing an estimated fifteen questions.);
Average Burden Hours Per Response: 1; and Estimated Total Annual Burden
Hours Requested: 500. The annualized total cost to respondents is
estimated at: $25,000. It is expected that the respondents will be
contacted vie e-mail and that their responses will be collected through
an Internet-accessible questionnaire. These measures will reduce the
burden on the respondents and the overall costs of administering the
study. Because different types of awards have been made with the
special type 1 diabetes funds, the questionnaire may be tailored such
that respondents will only be asked to answer a subset of questions
that pertain to their particular type of award(s). No respondent will
be asked to answer more than a total of fifteen questions, at least
one-third of which will be answered with a ``yes'' or ``no'' or a one-
word response. There are no Capital Costs, Operating or Maintenance
Costs to report.
Request For Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Whether the proposed collection of information is
necessary for the proper performance of the function of the agency,
including whether the information will have practical utility; (2) The
accuracy of the agency's estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (3) Ways to enhance the quality, utility, and
clarity of the information to be collected; and (4) Ways to minimize
the burden of the collection of information on those who are to
respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the data collection plans and
instruments, contact Dr. Shefa Gordon, Office of Scientific Program and
Policy Analysis, NIDDK, NIH, Building 31, Room 9A31, 9000 Rockville
Pike, Bethesda, MD 20892, or call non-toll-free number 301-496-6623 or
e-mail your request, including your address to:
gordonshefa@mail.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Dated: March 2, 2005.
Lynell Nelson,
Project Clearance Liaison, NIDDK, National Institutes of Health.
[FR Doc. 05-4674 Filed 3-9-05; 8:45 am]
BILLING CODE 4140-01-M